[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345988-105":59,"doc-detail-345988-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","from-probe-to-prodrug-immunoproteasome-activity-as-a-trigger-for-disease-selective-therapeutics","From probe to prodrug - immunoproteasome activity as a trigger for disease-selective therapeutics","","Developing therapies that selectively activate toxic payloads in diseased cells while sparing healthy tissue remains a major challenge in prodrug design. This work introduces an intracellular enzyme-based strategy that exploits inflammation-upregulated immunoproteasome activity for prodrug release. MMAE is conjugated to an immunoproteasome-selective peptide, enabling selective cleavage at low concentrations in cancer cells with preserved viability in healthy cells. In vivo validation in small cell lung cancer shows reduced tumor volume with limited toxicities, supporting broader applicability across immunoproteasome-upregulated cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-probe-to-prodrug-immunoproteasome-activity-as-a-trigger-for-disease-selective-therapeutics/345988/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-probe-to-prodrug-immunoproteasome-activity-as-a-trigger-for-disease-selective-therapeutics/345988.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What prodrug strategy does the study propose to improve disease selectivity?","Question",{"text":112,"@type":113},"The study proposes using immunoproteasome activity as an intracellular trigger to release a toxic therapeutic cargo specifically in diseased cells, avoiding reliance on surface antigen recognition.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is the toxic payload delivered and activated in cancer cells?",{"text":117,"@type":113},"MMAE is conjugated to an immunoproteasome-selective peptide so that the immunoproteasome cleaves the conjugate and releases the toxic compound in cancerous cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What in vivo evidence supports the approach?",{"text":121,"@type":113},"Using immunoproteasome prodrugs in vivo in small cell lung cancer leads to a significant reduction in tumor volume without significant toxicities.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345988,1790388754,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nFrom probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics  \nCody A. Loy 1,2, Yijun Gu 1, Samuel C. Kim3,4,5,6, Mariam V. Mohagheghi 3,4,5,6, Noah B. Trask3,4,5,6, Marina Suarez-Pizarro7,8, Lisa E. Wagar 3,4,5,6, Claudia A. Benavente 1,7,8 and Darci J. Trader 1,2,8,9 ✉  \n\n|  | Developing novel strategies that can exploit a cell's endogenous machinery to selectively release toxic compounds in diseased cells, while leaving healthy cells unaffected, is a challenging task to accomplish. An established approach involves antigen recognition on tumor cells, enabling targeted delivery of prodrugs in which a cytotoxic compound is appended to an antibody by a cleavable linker. However, this strategy depends on the presence of highly expressed surface markers for which antibodies can be developed, limiting its applicability to cancers that display these markers. A new approach that could rely on disease-speciﬁc expression of an intracellular enzyme, which can be more broadly targeted, could expand the therapeutic potential of prodrugs clinically. Here, we demonstrate that the immunoproteasome, an isoform of the standard proteasome that is upregulated under conditions of inﬂammation, has the potential to be harnessed as a prodrug release enzyme. We conjugate the highly toxic and widely used therapeutic cargo MMAE onto an immunoproteasome-selective peptide and demonstrate its selective release in cancerous cells at low nM to pM concentrations, while healthy cells remain viable. We also establish the ﬁrst translational validation that using immunoproteasome prodrugs in vivo leads to a signiﬁcant reduction in tumor volume without signiﬁcant toxicities in small cell lung cancer. We anticipate this approach to be broadly applicable, as the immunoproteasome is upregulated in a variety of cancers |  |  |  |\n| --- | --- | --- | --- | --- |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n|  |  |  |  |  |\n| and does not require antibody recognition to be |  | effective. |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)1 | 1:330 | ; [https://doi.org/10.1038/s41392-026-02835-w](https://doi.org/10.1038/s41392-026-02835-w) |  |\n|  |  |  |  |  |\n\nINTRODUCTION  \nA major challenge in drug discovery remains the ability to target a diseased cell population while leaving the healthy tissue unaffected. Several strategies have been applied to overcome this such as targeting a protein that is overexpressed in the diseased cell population, in silico prediction and optimization,1,2 and tissue-speciﬁc delivery systems.3 Although these methods have shown promise in improving off-target toxicities, identifying methods that have wide therapeutic windows is still a challenge. One method that has been employed widely is the use of maskinga toxic compound with a pro-moiety sequence that can be removed once the compound has entered the diseased environment.4 This removal can be performed by external sources such as thermal-or photo-cleavable groups, enzymes that are upregulated or only expressed in the diseased environment, or by metabolic changes to the molecule that can be converted into the active compound upon entering the diseased cell.5,6 One of the most popular approaches to this prodrug strategy is the use of antibody-drug-conjugates (ADCs) .7,8 ADCs typically rely on the recognition of an antigen expressed on the surface of the diseased cell that can direct the therapy to, leading to internalization of the compound into lysosomes, where the acidic environment cleaves the pro-moiety sequence, allowing the toxic compound to be released and perform its intended mechanism of action. Although  \nthis method is effective at ","cbCaihGG3iNYGlDU","https://ap.wps.com/l/cbCaihGG3iNYGlDU","pdf",3902460,15,"English","# Introduction\n## Targeted prodrug strategies and ADC limitations\n## Proteasome biology and immunoproteasome catalytic preferences","[{\"question\":\"What prodrug strategy does the study propose to improve disease selectivity?\",\"answer\":\"The study proposes using immunoproteasome activity as an intracellular trigger to release a toxic therapeutic cargo specifically in diseased cells, avoiding reliance on surface antigen recognition.\"},{\"question\":\"How is the toxic payload delivered and activated in cancer cells?\",\"answer\":\"MMAE is conjugated to an immunoproteasome-selective peptide so that the immunoproteasome cleaves the conjugate and releases the toxic compound in cancerous cells.\"},{\"question\":\"What in vivo evidence supports the approach?\",\"answer\":\"Using immunoproteasome prodrugs in vivo in small cell lung cancer leads to a significant reduction in tumor volume without significant toxicities.\"}]","From probe to prodrug - immunoproteasome activity as a trigger for disease-selective therapeutics | PDF",1790059613,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8abec68500dcce8aee136ac2dfcfae53.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e63588fb41b1107e6d145ac0bc77676.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dff0556f5e43b3aae7b840277fe5687b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/132573d3ce067e3f3edd863e3af9f497.webp",980,1301]